Rapamycin (Sirolimus, RAPA, Rapamune, AY-22989, NSC 226080, LCP-Siro, SILA 9268A, CAS 53123-88-9), >99%

LC Laboratories' Product Number R-5000 - Rapamycin (Sirolimus, RAPA, Rapamune, AY-22989, NSC 226080, LCP-Siro, SILA 9268A), >99% - for research use only. Immunosuppressant, related to FK-506, but without calcineurin inhibitory activity even when complexed to FK-506 binding protein. Selectively blocks signaling that leads to p70 S6 kinase activation (IC50 = 50 pM). Lymphokine-induced cell proliferation at the G1 phase is inhibited and apoptosis in a murine B cell line is induced by rapamycin. Rapamycin arrests the Saccharomyces cerevisiae cell cycle irreversibly in the G1 phase. Due to a different mechanism of action than cyclosporin and FK506, rapamycin may prove to be important in organ transplant patient therapy. Fewer side effects than the standard anti-rejection treatments have been observed. Proliferation of activated T cells, but not apoptosis, is blocked by rapamycin. The induction of apoptosis of rejection-causing T cells reduces the tendency towards transplant rejection. Quantitation of rapamycin, metabolites and related compounds such as everolimus and FK-506 in blood, tissues and other matrices is offered as a service by Rocky Mountain Labs. This firm is not affiliated with LC Labs.
Supplier LC Laboratories
Product # R-5000
Sku # R-5000_200mg
Pricing 200 mg, $98.00

Citations for this product:

» View all 36 citations
Feedback